InnoCan Pharma Corporation focuses on developing drug delivery platforms that combine cannabidiol (CBD) with pharmaceutical ingredients. The company boasts a strong gross margin of 90.8%, indicating effective cost management, but faces challenges with negative EBITDA and net margins, suggesting operational inefficiencies. Its high current and quick ratios reflect solid liquidity, while a low debt-to-equity ratio indicates manageable leverage. However, the market cap of $8.55M raises concerns about overall valuation despite the high margins, highlighting potential investor skepticism regarding future profitability.
Loading financial metrics...
Revenue fell 18.4% year-over-year from $28.8M to $23.5M. The decline has persisted for multiple quarters.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.5M over the last year.
Exceptional gross margin of 90.5% indicates strong pricing power and competitive moat.
Fortress balance sheet: cash covers total debt 3.8×, providing significant financial flexibility.
Excellent liquidity with current ratio of 5.3x ensures operational stability.
Low debt-to-revenue ratio of 7.1% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)